DOI QR코드

DOI QR Code

ABO Blood Group, Epstein-Barr virus Infection and Prognosis of Patients with Non-metastatic Nasopharyngeal Carcinoma

  • Zhang, Ya-Xiong (Department of Medical Oncology, Sun Yat-sen University Cancer Center) ;
  • Kang, Shi-Yang (Department of Medical Oncology, Sun Yat-sen University Cancer Center) ;
  • Chen, Gang (Department of Medical Oncology, Sun Yat-sen University Cancer Center) ;
  • Fang, Wen-Feng (Department of Medical Oncology, Sun Yat-sen University Cancer Center) ;
  • Wu, Xuan (Department of Medical Oncology, Sun Yat-sen University Cancer Center) ;
  • You, Hua-Jing (Department of Medical Oncology, Sun Yat-sen University Cancer Center) ;
  • He, Da-Cheng (Department of Medical Oncology, Sun Yat-sen University Cancer Center) ;
  • Cao, Ya-Lin (Department of Medical Oncology, Sun Yat-sen University Cancer Center) ;
  • Liang, Wen-Hua (Department of Medical Oncology, Sun Yat-sen University Cancer Center) ;
  • Zhang, Li (Department of Medical Oncology, Sun Yat-sen University Cancer Center)
  • Published : 2014.09.15

Abstract

Background: A prior study showed blood type A/AB to be associated with an increased risk of nasopharyngeal carcinoma (NPC) compared to subjects with blood type O. However, the relationship between ABO blood groups and prognosis of NPC patients is still questionable. In addition, whether Epstein-Barr virus (EBV) infection is associated with prognosis of NPC patients with different ABO blood groups is unclear. Materials and Methods: We conducted univariate and multivariable Cox regression analyses based on a consecutive cohort of 1,601 patients to investigate the above issues. Results: There was no significant difference in overall survival (OS) between different ABO blood groups (p=0.629), neither between A vs. non-A blood groups (p=0.895) nor AB vs. non-AB blood group (p=0.309) in univariate analyses and after adjusting for other factors. Interaction tests revealed that high immunoglobulin A against Epstein-Barr virus viral capsid antigen (VcA-IgA) level was associated with a favorable prognosis in male patients with UICC stage II disease who had an A blood type (p=0.008), compared with those with non-A blood type. In addition, male patients with an A blood group with a high blood lymphocyte level showeda tendency towards better survival in UICC stage III (p=0.096). Conclusions: ABO blood group status is not associated with the prognosis of patients with NPC. Additionally, blood group A male NPC patients with high VcA-IgA level or high blood lymphocyte counts might be correlated with a favorable prognosis in UICC stage II or III, respectively.

Keywords

Nasopharyngeal carcinoma;ABO blood group;Epstein-Barr virus;VcA-IgA;blood lymphocyte

References

  1. Cai YL, Li J, Lu AY, et al (2013). Prognostic significance of serum anti-Epstein-Barr virus antibodies in nasopharyngeal carcinoma. Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi, 27, 119-22
  2. Cheng WM, Chan KH, Chen HL, et al (2002). Assessing the risk of nasopharyngeal carcinoma on the basis of EBV antibody spectrum. Int J Cancer, 97, 489-92. https://doi.org/10.1002/ijc.1641
  3. Chien YC, Chen JY, Liu MY, et al (2001). Serologic markers of Epstein-Barr virus infection and nasopharyngeal carcinoma in Taiwanese men. N Eng J Med, 345, 1877-82. https://doi.org/10.1056/NEJMoa011610
  4. Chua D, Huang J, Zheng B, et al (2001). Adoptive transfer of autologous Epstein-Barr virus-specific cytotoxic T cells for nasopharyngeal carcinoma. Int J Cancer, 94, 73-80. https://doi.org/10.1002/ijc.1430
  5. Comoli P, De Palma R, Siena S, et al (2004). Adoptive transfer of allogeneic Epstein-Barr virus (EBV)-specific cytotoxic T cells with in vitro antitumor activity boosts LMP2-specific immune response in a patient with EBV-related nasopharyngeal carcinoma. Ann Oncol, 15, 113-7. https://doi.org/10.1093/annonc/mdh027
  6. Fan H, Nicholls J, Chua D, et al (2004). Laboratory markers of tumor burden in nasopharyngeal carcinoma: a comparison of viral load and serologic tests for Epstein-Barr virus. Int J Cancer, 112, 1036-41. https://doi.org/10.1002/ijc.20520
  7. Fogg M, Murphy JR, Lorch J, Posner M, Wang F (2013). Therapeutic targeting of regulatory T cells enhances tumor-specific CD8+ T cell responses in Epstein-Barr virus associated nasopharyngeal carcinoma. Virology, 441, 107-13. https://doi.org/10.1016/j.virol.2013.03.016
  8. Gao S, Worm J, Guldberg P, et al (2004). Genetic and epigenetic alterations of the blood group ABO gene in oral squamous cell carcinoma. Int J Cancer, 109, 230-7. https://doi.org/10.1002/ijc.11592
  9. Gates MA, Wolpin BM, Cramer DW, Hankinson SE, Tworoger SS (2011). ABO blood group and incidence of epithelial ovarian cancer. Int J Cancer, 128, 482-6. https://doi.org/10.1002/ijc.25339
  10. Han BL, Xu XY, Zhang CZ, et al (2012). Systematic review on Epstein-Barr Virus (EBV) DNA in diagnosis of nasopharyngeal carcinoma in Asian populations. Asian Pac J Cancer Prev, 13, 2577-81. https://doi.org/10.7314/APJCP.2012.13.6.2577
  11. Hashim NAN, Ramzi NH, Velapasamy S, et al (2012). Identification of genetic and non-genetic risk factors for nasopharyngeal carcinoma in a southeast Asian population. Asian Pac J Cancer Prev, 13, 6005-10. https://doi.org/10.7314/APJCP.2012.13.12.6005
  12. He C, Zhuang HG, Zhang WY (1999). The reaction and biological behavior of immune cells is associated with the prognosis of nasopharyngeal carcinoma in UICC stage III. Chinese J Pathol, 28, 115-8.
  13. Henle G, Henle W (1976). Epstein-Barr virus-specific IgA serum antibodies as an outstanding feature of nasopharyngeal carcinoma. Int J Cancer, 17, 1-7. https://doi.org/10.1002/ijc.2910170102
  14. Ho HC, Ng MH, Kwan HC, Chau JC (1976). Epstein-Barr virus specific IgA and IgG serum antibodies in nasopharyngeal carcinoma. Br J Cancer, 34, 655-60. https://doi.org/10.1038/bjc.1976.228
  15. Hosoi E (2008). Biological and clinical aspects of ABO blood group system. J Med Invest, 55, 174-82. https://doi.org/10.2152/jmi.55.174
  16. Huang TR, Zhang SW, Chen WQ, et al (2012). Trends in nasopharyngeal carcinoma mortality in China, 1973-2005. Asian Pac J Cancer Prev, 13, 2495-502. https://doi.org/10.7314/APJCP.2012.13.6.2495
  17. Iodice S, Maisonneuve P, Botteri E, Sandri MT, Lowenfels AB (2010). ABO blood group and cancer. Eur J Cancer, 46, 3345-50. https://doi.org/10.1016/j.ejca.2010.08.009
  18. Jemal A, Bray F, Center MM, et al (2011). Global cancer statistics. CA Cancer J Clin, 61, 69-90. https://doi.org/10.3322/caac.20107
  19. Jia WH, Luo XY, Feng BJ, et al (2010). Traditional Cantonese diet and nasopharyngeal carcinoma risk: a large-scale casecontrol study in Guangdong, China. BMC Cancer, 10, 446. https://doi.org/10.1186/1471-2407-10-446
  20. Ji X, Zhang W, Xie C, et al (2011). Nasopharyngeal carcinoma risk by histologic type in central China: impact of smoking, alcohol and family history. Int J Cancer, 129, 724-32. https://doi.org/10.1002/ijc.25696
  21. Joh HK, Cho E, Choueiri TK (2012). ABO blood group and risk of renal cell cancer. Cancer Epidemiol, 36, 528-32. https://doi.org/10.1016/j.canep.2012.07.001
  22. Low WK, Leong JL, Goh YH, Fong KW (2000). Diagnostic value of Ep-stein-Barr viral serology in nasopharyngeal carcinoma. Otolaryngol Head Neck Surg, 123, 505-7. https://doi.org/10.1067/mhn.2000.108201
  23. Ouyang PY, Su Z, Mao YP, Liu Q, Xie FY (2013). Prognostic value of ABO blood group in southern Chinese patients with established nasopharyngeal carcinoma. Br J Cancer advance online publication, 559.
  24. Ozelius LJ, Kwiatkowski DJ, Schuback DE, et al (1992). A genetic linkage map of human chromosome 9q. Genomics, 14, 715-20. https://doi.org/10.1016/S0888-7543(05)80173-9
  25. Rickinson AB, Kieff E (2007) Epstein-Barr virus, 5th ed. eds knipe, D.M.and howley, P.M. fields virology. Lippincott Williams & Wilkins, Philadelphia, PA 2655-700.
  26. Sam CK, Prasad U, Pathmanathan R (1989). Serological markers in the diagnosis of histopathological types of nasopharyngeal carcinoma. Eur J Surg Oncol, 15, 357-60.
  27. Secondino S, Zecca M, Licitra L, et al (2012). T-cell therapy for EBV-associated nasopharyngeal carcinoma: preparative lymphodepleting chemotherapy does not improve clinical results. Ann Oncol, 23, 435-41. https://doi.org/10.1093/annonc/mdr134
  28. Sheng L, Sun X, Zhang L, Su D (2013). ABO blood group and nasopharyngeal carcinoma risk in a population of Southeast China. Int J Cancer, 133, 893-7. https://doi.org/10.1002/ijc.28087
  29. Straathof KC, Bollard CM, Popat U, et al (2005). Treatment of nasopharyngeal carcinoma with Epstein-Barr virus-specific T lymphocytes. Blood, 105, 1898-904. https://doi.org/10.1182/blood-2004-07-2975
  30. Straathof KC, Bollard CM, Rooney CM, Heslop HE (2003). Immunotherapy for Epstein-Barr virus-associated cancers in children. Oncologist, 8, 83-98. https://doi.org/10.1634/theoncologist.8-1-83
  31. Thompson MP, Kurzrock R (2004). Epstein-Barr virus and cancer. Clin Cancer Res, 10, 803-21. https://doi.org/10.1158/1078-0432.CCR-0670-3
  32. Tiwawech D, Srivatanakul P, Karaluk A, Ishida T (2003). Significance of plasma IgA and IgG antibodies to Epstein-Barr virus early and viral capsid antigens in Thai nasopharyngeal carcinoma. Asian Pac J Cancer Prev, 4, 113-8.
  33. Wang Z, Liu L, Ji J, et al (2012). ABO Blood Group System and Gastric Cancer: A Case-Control Study and Meta-Analysis. In. J Mo. Sci, 13, 13308-21. https://doi.org/10.3390/ijms131013308
  34. Wolpin BM, Chan AT, Hartge P, et al (2009). ABO blood group and the risk of pancreatic cancer. J Natl Cancer Inst, 101, 424-31. https://doi.org/10.1093/jnci/djp020
  35. Zhang BL, He N, Huang YB et al (2014). ABO blood groups and risk of cancer: a systematic review and meta-analysis. Asian Pac J Cancer Prev, 15, 4643-50. https://doi.org/10.7314/APJCP.2014.15.11.4643

Cited by

  1. Prognostic Correlations between ABO Blood Group and Pre-Treatment Plasma Epstein-Barr Virus DNA in Patients with Nasopharyngeal Carcinoma Receiving Intensity-Modulated Radiotherapy vol.11, pp.11, 2016, https://doi.org/10.1371/journal.pone.0166194